Based in the Washington, D.C. office, Abram Ellis is a Partner and Co-Head of the Firm’s International Trade Regulation Practice. His practice focuses on antitrust matters—including class action litigation, antitrust merger review and antitrust counseling—and on regulatory issues present in international and cross-border transactions.
Abram regularly represents clients in some of the most high-profile, pending private antitrust actions. He has also successfully helped clients navigate the antitrust merger review process, and regularly consults and advises clients on potential business activities and strategies, new industry developments and contracting activities. Abram is recognized as a “Future Star” by Euromoney’s Benchmark Litigation and a “Next Generation Partner” by The Legal 500, where he is described as “highly regarded in the market,” “a leader in the field,” and “a good strategist.” Sources also say that he is “a phenomenal advisor—both on day to day advisory matters, but also on complex litigation . . . He is a star.” He has also been recognized by Super Lawyers as a “Rising Star” for Antitrust Litigation, by Lawdragon’s “500 Leading Litigators in America” guide for his work involving antitrust and competition law, and The American Lawyer.
Abram also has substantial experience advising clients regarding U.S. laws relevant to international and cross-border transactions, including advising clients on matters involving regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Control and the U.S. Commerce Department’s Bureau of Industry and Security, the Foreign Corrupt Practices Act, and the Committee on Foreign Investment in the U.S.
He graduated from the University of Michigan Law School in 2005, cum laude, after obtaining an M.A. in International Relations from the Johns Hopkins University School of Advanced International Studies and a B.A. from Brigham Young University.
Updated Oct 2025
Change Healthcare in its $13.8 billion acquisition by UnitedHealth Group, which was named “Merger Control Matter of the Year – Americas” at Global Competition Review’s GCR Awards 2023.
HCA Healthcare in FTC’s first lawsuit over COPA.
RPM International and The Euclid Chemical Company in the dismissal of an antitrust action regarding concrete admixtures and cement additives.
JPMorgan in the complete dismissal of multidistrict LIBOR litigation.
- Amedisys in DOJ litigation to block its proposed $3.3 billion acquisition by UnitedHealth Group.
- Appellate
- Class action
- Competition/antitrust
- EU Competition
- Government and regulatory
- Trade and customs
- Banking
- Financial services
- Healthcare
- Industrials
- Pharmaceutical and life sciences
- J.D., cum laude - University of Michigan Law School - 2005
- M.A., John C. Foster Award, SAIS Review Book Review Editor - Johns Hopkins School of Advanced International Studies - 2002
- B.A. - Brigham Young University - 2000
- New York State Bar Association
- U.S. Court of Appeals for the Second Circuit - 2017
- District of Columbia - 2006
- New York - 2006